Dr Fei-Li Zhao

Dr Fei-Li Zhao

Conjoint Senior Lecturer

School of Biomedical Sciences and Pharmacy

Career Summary

Biography

Dr Fei-Li Zhao is a Conjoint Senior Lecturer at the University of Newcastle. Dr Zhao has experiences and expertise in health technology assessment (HTA), economic evaluation using trial and real-world data, quality of life and preference measurement, and health service research. She has acquired over 10 years of national and international experiences in leading health economics and HTA projects to inform a wide range of decision-making, working effectively with various stakeholders including academia, industry, non-government and government organisations. This includes providing high quality, expert health economics advice and support to the Pharmaceutical Benefits Advisory Committee (PBAC) for national reimbursement decision makings of pharmaceuticals and vaccines. The impact of her research and practice can be proved by the implementation of policy and HTA recommendations, a number of reports, series papers published in high-quality journals, and collaborations built across sections locally and internationally. She is recognized as an active health economics researcher and regularly presents in international and national conferences.


Qualifications

  • Doctor of Philosophy, University of Newcastle
  • Bachelor of Science, China Pharmaceutical University - China
  • Master of Science, Graduat University of Chinese Academy of Sciences

Keywords

  • Health Economics and Outcomes Research
  • Health Policy
  • Health Service Research
  • Health Technology Assessment
  • Public Health

Fields of Research

Code Description Percentage
111799 Public Health and Health Services not elsewhere classified 30
140208 Health Economics 60
111503 Clinical Pharmacy and Pharmacy Practice 10
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Chapter (1 outputs)

Year Citation Altmetrics Link
1996 Rotter T, Kinsman L, Machotta A, Zhao F, van der Weijden T, Ronellenfitsch U, Scott SD, 'Clinical pathways for primary care: effects on professional practice, patient outcomes, and costs', Cochrane Database of Systematic Reviews, John Wiley & Sons, Ltd (1996)
DOI 10.1002/14651858.cd010706
Citations Scopus - 9
Co-authors Leigh Kinsman

Journal article (14 outputs)

Year Citation Altmetrics Link
2016 Gao L, Hu H, Zhao F-L, Li S-C, 'Can the Direct Medical Cost of Chronic Disease Be Transferred across Different Countries? Using Cost-of-Illness Studies on Type 2 Diabetes, Epilepsy and Schizophrenia as Examples', PLOS ONE, 11 (2016) [C1]
DOI 10.1371/journal.pone.0147169
Citations Scopus - 6Web of Science - 5
Co-authors Shuchuen Li
2015 Lang DL, Zhao FL, Robertson J, 'Prevention of postpartum haemorrhage: Cost consequences analysis of misoprostol in low-resource settings', BMC Pregnancy and Childbirth, (2015) [C1]

© 2015 Lang et al. Background: While inferior to oxytocin injection in both efficacy and safety, orally administered misoprostol has been included in the World Health Organization... [more]

© 2015 Lang et al. Background: While inferior to oxytocin injection in both efficacy and safety, orally administered misoprostol has been included in the World Health Organization Model List of Essential Medicines for use in the prevention of postpartum haemorrhage (PPH) in low-resource settings. This study evaluates the costs and health outcomes of use of oral misoprostol to prevent PPH in settings where injectable uterotonics are not available. Methods: A cost-consequences analysis was conducted from the international health system perspective, using data from a recent Cochrane systematic review and WHO's Mother-Baby Package Costing Spreadsheet in a hypothetical cohort of 1000 births in a mixed hospital (40 % births)/community setting (60 % births). Costs were estimated based on 2012 US dollars. Results: Using oxytocin in the hospital setting and misoprostol in the community setting in a cohort of 1000 births, instead of oxytocin (hospital setting) and no treatment (community setting), 22 cases of PPH could be prevented. Six fewer women would require additional uterotonics and four fewer women a blood transfusion. An additional 130 women would experience shivering and an extra 42 women fever. Oxytocin/misoprostol was found to be cost saving (US$320) compared to oxytocin/no treatment. Conclusions: Our findings confirm that, even though misoprostol is not the optimum choice in the prevention of PPH, misoprostol could be an effective and cost-saving choice where oxytocin is not or cannot be used due to a lack of skilled birth attendants, inadequate transport and storage facilities or where a quality assured oxytocin product is not available. These benefits need to be weighed against the large number of additional side effects such as shivering and fever, which have been described as tolerable and of short duration.

DOI 10.1186/s12884-015-0749-z
Citations Scopus - 4Web of Science - 4
Co-authors Danielle Lang
2015 Gao L, Zhao FL, Li SC, 'Efficacy and Safety of Thrombin-Receptor Antagonist (Atopaxar and Vorapaxar) in Patients with Acute Coronary Syndrome or Coronary Artery Disease-A Meta-Analysis of Randomized Controlled Trials', Value in Health Regional Issues, 6 22-32 (2015)

© 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Background: Meta-analysis for the efficacy and safety data of thrombin-receptor antagonist (TRA) ... [more]

© 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Background: Meta-analysis for the efficacy and safety data of thrombin-receptor antagonist (TRA) based on patients with acute coronary syndrome (ACS) or coronary artery disease (CAD) and indirect comparisons between TRAs were not available. Objectives: We intended to synthesize the primary end points based on different patient populations (ACS or CAD) as well as perform indirect comparison between two newly invented antiplatelet agents atopaxar and vorapaxar. Methods: A literature search was performed in MEDLINE, Embase, and Cochrane Library. Incidences of major adverse cardiovascular events (MACEs) and bleeding events according to thrombolysis in myocardial infarction were selected as primary outcomes, whereas adverse effects were considered as secondary outcomes. Corresponding results were synthesized using Revman 5.1 according to ACS or CAD cohorts. Results: Among the seven included randomized controlled trials, the efficacy end points in the TRA treatment group were favorable compared with placebo. Specifically, the odds ratio (OR) of MACEs was 0.80 (95% confidence interval [CI] 0.52-1.22) for patients with ACS and 0.74 (95% CI 0.53-1.05) for the cohort with CAD. The events of bleeding were unanimously superior in the placebo arm for both cohorts. The indirect comparison showed a superior trend in favor of atopaxar over vorapaxar in occurrences of MACEs (OR 0.93; 95% CI 0.38-1.32), myocardial infarction (OR 0.52; 95% CI 0.13-0.95), and cardiovascular death (OR 0.82; 95% CI 0.12-4.24) and caused less incidence of bleeding. Conclusions: Besides being more effective than placebo in improving the incidence of MACEs but with a higher risk of bleeding, TRAs may exert different effects in patients with ACS and CAD. Indirect comparisons also suggested that atopaxar might be better than vorapaxar in lowering the incidence of MACEs, myocardial infarction, and cardiovascular death and at the same time with lower risks of bleeding.

DOI 10.1016/j.vhri.2015.01.003
Citations Scopus - 1
Co-authors Shuchuen Li
2014 Wu J, Han Y, Zhao F-L, Zhou J, Chen Z, Sun H, 'Validation and comparison of EuroQoL-5 dimension (EQ-5D) and Short Form-6 dimension (SF-6D) among stable angina patients', HEALTH AND QUALITY OF LIFE OUTCOMES, 12 (2014)
DOI 10.1186/s12955-014-0156-6
Citations Scopus - 30Web of Science - 29
2013 Zhao F-L, Xie F, Hu H, Li S-C, 'Transferability of Indirect Cost of Chronic Disease: A Systematic Review and Meta-Analysis', PHARMACOECONOMICS, 31 501-508 (2013)
DOI 10.1007/s40273-013-0053-6
Citations Scopus - 12Web of Science - 12
Co-authors Shuchuen Li
2013 Gao L, Xia L, Zhao F-L, Li S-C, 'Clinical efficacy and safety of the newer antiepileptic drugs as adjunctive treatment in adults with refractory partial-onset epilepsy: A meta-analysis of randomized placebo-controlled trials', EPILEPSY RESEARCH, 103 31-44 (2013) [C1]
DOI 10.1016/j.eplepsyres.2012.06.005
Citations Scopus - 25Web of Science - 23
Co-authors Shuchuen Li
2013 Zhao F, Gao L, Li S, 'Burden of Disease Studies in the Asia-Pacific Region: Are There Enough being Performed to Provide Information for Evidence-Based Health Policy?', Value in Health Regional Issues, 2 152-159 (2013) [C1]
DOI 10.1016/j.vhri.2013.02.007
Citations Scopus - 3
Co-authors Shuchuen Li
2012 Gao L, Zhao F, Li SC, 'Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China', International Journal of Technology Assessment in Health Care, 28 436-444 (2012) [C1]
Citations Scopus - 15Web of Science - 14
Co-authors Shuchuen Li
2012 Gao L, Zhao F, Li SC, 'Statin is a reasonable treatment option for patients with polycystic ovary syndrome: A meta-analysis of randomized controlled trials', Experimental and Clinical Endocrinology and Diabetes, 120 367-375 (2012) [C1]
Citations Scopus - 37Web of Science - 32
Co-authors Shuchuen Li
2011 Zhao F, Yue M, Yang H, Wang TA, Wu J-H, Li SC, 'Willingness to pay per quality-adjusted life year: Is one threshold enough for decision-making? Results from a study in patients with chronic prostatitis', Medical Care, 49 267-272 (2011) [C1]
Citations Scopus - 30Web of Science - 24
Co-authors Shuchuen Li
2010 Zhao F, Yue M, Yang H, Wang T, Wu J-H, Li SC, 'Health-related quality of life in Chinese patients with chronic prostatitis/chronic pelvic pain syndrome', Quality of Life Research, 19 1273-1283 (2010) [C1]
DOI 10.1007/s11136-010-9697-2
Citations Web of Science - 9
Co-authors Shuchuen Li
2006 Zhao F-L, Hu J-IH, Zhu X-Z, 'Monocyte-mediated rotenone neurotoxicity towards human neuroblastoma SH-SY5Y: Role of mitogen-activated protein kinases', BIOLOGICAL & PHARMACEUTICAL BULLETIN, 29 1372-1377 (2006)
DOI 10.1248/bpb.29.1372
Citations Scopus - 4Web of Science - 4
2006 Liu DZ, Zhao FL, Liu J, Li XQ, Ye Y, Zhu XZ, 'Potentiation of adenosine A

The effect of paeoniflorin (PF), a major constituent isolated from Paeony radix, on N6-Cyclopentyladenosine (CPA), a selective adenosine A 1 receptor (A1 receptor) agonist, induce... [more]

The effect of paeoniflorin (PF), a major constituent isolated from Paeony radix, on N6-Cyclopentyladenosine (CPA), a selective adenosine A 1 receptor (A1 receptor) agonist, induced antinociception was examined in mice. In the tail-pressure test, CPA (0.05, 0.1, 0.2 mg/kg, s.c.) could induce antinociception in a dose-dependent manner. PF (5, 10, 20 mg/kg, s.c.) alone failed to exhibit any antinociceptive effect in mice; however, pretreatment of PF (20 mg/kg, s.c.) could significantly enhance CPA-induced antinociception. Additionally, pretreatment of 8-Cyclopentyl-1,3- dipropylxanthine (DPCPX, 0.25 mg/kg, s.c.), a selective A1 receptor antagonist, could antagonize the antinociceptive effect of combining CPA with PF. Furthermore, in the competitive binding experiments, PF did not displace the binding of [3H]-8-Cyclopentyl-1,3-dipropylxanthine ([ 3H]-DPCPX) but displaced that of [3H]-2-Chloro-N 6-cyclopentyladenosine ([3H]-CCPA, a selective A 1 receptor agonist) to the membrane preparation of rat cerebral cortex. These results suggested that PF might selectively increase the binding and antinociceptive effect of CPA by binding with A1 receptor. © 2006 Pharmaceutical Society of Japan.

DOI 10.1248/bpb.29.1630
Citations Scopus - 14
2005 Xiao L, Zhao FL, Zhu XZ, 'Down regulation of cyclooxygenase-2 is involved in delayed neuroprotection by ischemic preconditioning in rats', Acta Pharmacologica Sinica, 26 441-446 (2005)

Aim: To examine whether the prostaglandins (PGs) pathway is involved in triggering delayed neuroprotection by ischemic preconditioning (IPC) and evaluate the effects of IPC on cyc... [more]

Aim: To examine whether the prostaglandins (PGs) pathway is involved in triggering delayed neuroprotection by ischemic preconditioning (IPC) and evaluate the effects of IPC on cyclooxygenase-2 (COX-2) expression following focal cerebral ischemia and reperfusion in rats. Methods: IPC was induced by 10 min of saline infusion into the left internal carotid artery with the right common carotid artery clamped at the same time. Middle cerebral artery occlusion (MCAO) and reperfusion model was produced using intraluminal filament method. Results: IPC 48 h prior to MCAO significantly reduced infarct area as compared with MCAO alone. A nonselective inhibitor of COX indomethacin (3 mg/kg ip) applied 1 h prior to or 1 h after IPC failed to affect its protective effects. IPC had no direct effect on the cortex COX-2 mRNA and protein expression 72 h later, but decreased the expression of COX-2 mRNA and protein following ischemia and reperfusion insult. Conclusion: PGs pathways was not involved in triggering delayed neuroprotection by IPC, and IPC induced down-regulation of COX-2 following focal cerebral ischemia and reperfusion in rats in vivo. © 2005 CPS and SIMM.

DOI 10.1111/j.1745-7254.2005.00064.x
Citations Scopus - 5
Show 11 more journal articles

Conference (6 outputs)

Year Citation Altmetrics Link
2012 Zhao F, Xie F, Li SC, 'Transferability of indirect cost of chronic disease: A systematic review and meta-analysis', Value in Health: ISPOR 15th Annual European Congress and ISPOR 5th Asia-Pacific Conference, Berlin, Germany (2012) [E3]
Co-authors Shuchuen Li
2010 Zhao F, Yue M, Wu JH, Yang H, Wang T, Li SC, 'Validation and comparison of euroqol and short form 6D in chronic prostatitis patients', Value in Health, Atlanta, GA (2010) [E3]
DOI 10.1111/j.1524-4733.2010.00728.x
Citations Scopus - 33Web of Science - 30
Co-authors Shuchuen Li
2010 Zhao F, Yue M, Yang H, Wang T, Wu JH, Li SC, 'Willingness to pay per quality adjusted life-year: Is one threshold applicable for all decision-making', Value in Health, Phuket, Thailand (2010) [E3]
Citations Web of Science - 3
Co-authors Shuchuen Li
2010 Zhao F, Yue M, Yang H, Wang T, Wu JH, Li SC, 'Health-related quality of life in Chinese chronic prostatitis patients', Value in Health, Phuket, Thailand (2010) [E3]
DOI 10.1007/s11136-010-9697-2
Citations Scopus - 12
Co-authors Shuchuen Li
2009 Zhao F, Li SC, 'A systematic review of burden of disease studies in the Asia-Pacific region', Value in Health, Orlando, FL (2009) [E3]
DOI 10.1111/j.1524-4733.2009.00537_2.x
Co-authors Shuchuen Li
2009 Zhao F, Wu JH, Yue M, Li SC, 'Willingness to pay per quality-adjusted life year of chronic prostatits patients in China', Value in Health, Paris, France (2009) [E3]
Co-authors Shuchuen Li
Show 3 more conferences
Edit

Grants and Funding

Summary

Number of grants 1
Total funding $5,826,326

Click on a grant title below to expand the full details for that specific grant.


20121 grants / $5,826,326

External Evaluation of PBAC Submissions RFT 086/1112 $5,826,326

Funding body: Department of Health

Funding body Department of Health
Project Team Ms Danielle Lang, Doctor Barrie Stokes, Mr Marc Bevan, Mr Rob Bell, Doctor Fei-Li Zhao
Scheme Consultancy/Tender
Role Investigator
Funding Start 2012
Funding Finish 2016
GNo G1101212
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y
Edit

Dr Fei-Li Zhao

Position

Conjoint Senior Lecturer
School of Biomedical Sciences and Pharmacy
Faculty of Health and Medicine

Contact Details

Email feili.zhao@newcastle.edu.au
Edit